Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linerixibat for Pruritus in PBC (GLIMMER)
NCT02966834Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2017
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of linerixibat in primary biliary cholangitis (PBC) (6 arms), sponsored by GSK. Primary endpoint: Mean Change From Baseline in the Mean Worst Daily Itch Score at 16 weeks. Started Jan 2017; status: completed.
02
Drugs
linerixibat
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT02966834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966834.